CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 300 enrolled
Drug / intervention
Sarecyclinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04820673
NCT04820673N/ACompleted
CompareCT.gov

A Real-world Prospective Cohort Study of Patients With Moderate to Severe Acne Vulgaris Treated With Sarecycline (Seysara®) In Community Practice Settings in the U.S

Almirall, S.A.·observational·Posted Mar 29, 2021·Updated Oct 10, 2024

In Brief

An observational study evaluating Sarecycline for Acne Vulgaris. Completed, enrolled 300 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate the patient-reported outcomes (PROs) in terms of health-related quality of life (HRQoL) and signs of Acne Vulgaris (AV) among patients with moderate to severe non-nodular AV who are administered sarecycline (Seysara®) in real-world community practice settings in the United States (U.S). Investigator's Global Assessment (IGA) of AV and safety measures associated with use of sarecycline (Seysara®) will be assessed over the study observation period of 12 weeks. Clinicians will prescribe sarecycline (Seyara®) as per their own clinical judgment and standard practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMar 29, 2021
Enrollment StartMar 9, 2021
Primary CompletionMay 4, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.3 years ago

Interventions

Sarecyclinedrug

Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.